Breaking News, Financial News

Financial Report: Cangene

BAT and manufacturing revenues decline

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cangene   1Q Revenues: $24.6 million (-33%) 1Q Loss: $5.2 million (earnings were $5.9 million 1Q13) Comments: Results were impacted by reduced revenues for the company’s Botulism Antitoxin (BAT), along with decreased commercial contract manufacturing revenue. The prior-year quarter also included $3.3 million of revenue from sales of non-specialty plasma, which the company no longer sells. Loss in the quarter is attributed to higher R&D expenses related to the acquisition and developm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters